Document ID: chunk:federal_register_of_legislation:F2025C00158:clause:4_1:p35
Version: federal_register_of_legislation:F2025C00158
Segment Type: clause
Provision Reference: sch 4 cl 1 (pt 35/191)
Character Range: 9858371–9869415

with Authority Required procedures - Streamlined Authority Code 5461
                                                                                                                                                                                                                               The condition must be inadequately controlled with either a vitamin D analogue or potent topical corticosteroid as monotherapy; or
                                                                                                                                                                                                                               The condition must be inadequately controlled with combination use of a vitamin D analogue and potent topical corticosteroid;
                                                                                                                                                                                                                               Patient must be aged 18 years or older.
C5466               P5466          CN5466           Magnesium                                                                                                                                                                  Chronic renal disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Compliance with Authority Required procedures - Streamlined Authority Code 5466
                                                                                                                                                                                                                               Patient must be an Aboriginal or a Torres Strait Islander person.
C5470               P5470          CN5470           Clindamycin                                                                                                                                                                Gram-positive coccal infections
                                                                                                                                                                                                                               The condition must not be able to be safely and effectively treated with a penicillin.
C5472               P5472          CN5472           Pimecrolimus                                                                                                                                                               Atopic dermatitis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Compliance with Authority Required procedures - Streamlined Authority Code 5472
                                                                                                                                                                                                                               Short-term (up to 3 weeks) intermittent treatment
                                                                                                                                                                                                                               Patient must be at least 3 months of age;
                                                                                                                                                                                                                               The condition must be on the patient's face; or
                                                                                                                                                                                                                               The condition must be on the patient's eyelid; AND
                                                                                                                                                                                                                               Patient must have failed to achieve satisfactory disease control with intermittent topical corticosteroid therapy; AND
                                                                                                                                                                                                                               The condition must have been initially diagnosed more than three months prior to this treatment; AND
                                                                                                                                                                                                                               Patient must not receive more than two 15 g packs of PBS-subsidised pimecrolimus per 6-month period.
                                                                                                                                                                                                                               Failure to achieve satisfactory disease control with intermittent topical corticosteroid therapy is manifest by
                                                                                                                                                                                                                               (i) failure of the facial skin to clear despite at least 2 weeks of topical hydrocortisone 1% applied every day; or
                                                                                                                                                                                                                               (ii) failure of the facial skin to clear despite at least 1 week of a moderate or potent topical corticosteroid applied every day; or
                                                                                                                                                                                                                               (iii) clearing of the facial skin with at least 2 weeks of topical hydrocortisone 1% applied every day, but almost immediate and significant flare in facial disease (within 48 hours) upon stopping topical corticosteroids, occurring on at least 2 consecutive occasions; or
                                                                                                                                                                                                                               (iv) clearing of the facial skin with at least 1 week of a moderate or potent topical corticosteroid applied every day, but almost immediate and significant flare in facial disease (within 48 hours) upon stopping topical corticosteroids, occurring on at least 2 consecutive occasions
C5476               P5476          CN5476           Tobramycin                                                                                                                                                                 Perioperative use in ophthalmic surgery

C5477               P5477          CN5477           Tobramycin                                                                                                                                                                 Suspected Pseudomonal eye infection

C5482               P5482          CN5482           Pimecrolimus                                                                                                                                                               Atopic dermatitis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Compliance with Authority Required procedures - Streamlined Authority Code 5482
                                                                                                                                                                                                                               Patient must be at least 3 months of age;
                                                                                                                                                                                                                               The condition must be on the patient's face; or
                                                                                                                                                                                                                               The condition must be on the patient's eyelid; AND
                                                                                                                                                                                                                               Patient must have 1 or more of the following contraindications to topical corticosteroids:
                                                                                                                                                                                                                                (i) perioral dermatitis; (ii) periorbital dermatitis; (iii) rosacea; (iv) epidermal atrophy; (v) dermal atrophy; (vi) allergy to topical corticosteroids; (vii) cataracts; (viii) glaucoma; (ix) raised intraocular pressure; AND
                                                                                                                                                                                                                               Patient must not